Abstract
Objective: The present study was conducted to compare empagliflozin-metformin and empagliflozinlinagliptin upon uroprotection in Type 2 diabetes mellitus (T2DM).
Methodology: This analytical study of 12 weeks duration included 120 patients of T2DM with age between 40 to 70 years and glycated hemoglobin (HbA1c) between 6.5 to 9%. The patients were divided into two groups: Group A was given empagliflozin 12. 5 mg with metformin 500 mg once and Group B was given empagliflozin 10 mg with linagliptin 5 mg once on daily basis. Profiles of the patients were compared with these parameters at baseline, 4 weeks and 12 weeks including serum urea and creatinine, pus cells and glycosuria in urine.
Results: The baseline urea level in males was 14.06 mg/dL in Group A and 10.04 mg/dL in Group B with changes evident by week 12. Urea levels in females in Group A and B insignificantly increased with only minor changes in creatinine levels. In Group B males and females presented with pus cells at week 12 were 35% respectively, compared to 8% in both Group A males and females.
Conclusion: This study concludes that both empagliflozin-metformin and empagliflozin-linagliptin combinations in T2DM patients had insignificant effects on kidney but empagliflozinlinagliptin caused urinary tract infection. These finding are effective interims of group B treatment option. However, more research is needed in highlighting the safety in patients over longer periods of these drugs combinations.

Key words: Diabetes mellitus, DPP4 Inhibitors, metformin, SGLT-2 Inhibitors.